Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Computational Studies of 1-Hydrazinophthalazine (Hydralazine) as Antineoplasic Agent. Docking Studies on Methyltransferase

Author(s): Enrique Angeles, Victor HugoVazquez-Valadez, Oscar Vazquez-Valadez, Ana Maria Velazquez-Sanchez, Alberto Ramirez, Luisa Martinez, Sandra Diaz-Barriga, Andres Romero-Rojas, Gustavo Cabrera, Rafael Lopez-Castanares and Alfonso Duenas-Gonzalez

Volume 2, Issue 4, 2005

Page: [282 - 286] Pages: 5

DOI: 10.2174/1570180054038413

Price: $65

Abstract

Hydralazine is a drug used as anti-hypertensive, and recently reported to be a DNA methylation inhibitor able to demethylate and reactivate the expression of tumor suppressor genes in cancer. The aim of the present study was to explore the potential mechanism by which hydralazine inhibits DNA methylation. For this purpose, we assessed the structural and electronic properties between 1-hydrazinophthalazine (hydralazine) and a putative ligand methyltransferase.

Keywords: docking, hydralazine, dna methyltransferase, dna methylation inhibitor, tumor suppressor gene


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy